Variable | Value |
---|---|
No. of participants | 24 |
Demographics a | |
 Age (years) | 47.2 ± 11.1 |
 Height (cm) | 161.0 ± 4.3 |
 Weight (kg) | 61.9 ± 9.1 |
 Body surface area (m2) | 1.62 ± 0.13 |
Cardiovascular risk factors b | |
 Obesity (body mass index > 30 kg/m2) | 3 (12.5) |
 Age 65–79 years | 2 (8.3) |
 Arterial hypertension | 1 (5.0) |
 Diabetes | 0 (0.0) |
 Prior cardiovascular disease | 0 (0.0) |
HFA-ICOS baseline cardiovascular toxicity risk stratification b | |
 Moderate risk (with a total of 2 points) | 2 (8.3) |
 Low risk | 22 (91.7) |
 No risk factors | 19 (79.2) |
 One moderate risk with a total of 1 point | 3 (12.5) |
 Cardiac medication | 0 (0.0) |
 Left-/right-sided breast cancer b | 15 (62.5)/9 (37.5) |
Anti-HER2 therapy b | |
 Trastuzumab | 8 (33.3) |
 Trastuzumab and pertuzumab | 16 (66.7) |
 Interval time between baseline and follow-up MRI (days) | 107.5 ± 19.7 |